Revvity, Inc. logo
Revvity, Inc. (RVTY)
Compare

Revvity, Inc. (RVTY) Enterprise Value (EV): $13.36B

The enterprise value (EV) for Revvity, Inc. (RVTY) is $13.36B as of Wednesday, June 17, 2026.

RVTY Enterprise Value (EV) Metrics

ENTERPRISE VALUE (EV)

$13.36B

Enterprise Value Calculation

Market Cap

$10.91B

+

Total Debt

$3.37B

Cash

$919.87M

=

Enterprise Value

$13.36B

EV-Based Valuation Multiples

Why use EV instead of Market Cap?

  • EV accounts for debt - an acquirer must pay or assume it
  • EV deducts cash - the acquirer effectively receives it
  • EV enables fair comparison of companies with different capital structures
  • EV-based ratios (EV/EBITDA, EV/Sales) are capital structure neutral

Revvity, Inc. Enterprise Value (EV) Formula & Definition

Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Revvity, Inc. Enterprise Value (EV) FAQ

What is the enterprise value (EV) for Revvity, Inc. (RVTY)?
The enterprise value (EV) for RVTY stock is $13.36B.

About Revvity, Inc.

Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.

Waltham, MA
11,000 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Prahlad R. Singh